Literature DB >> 33483600

Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAFV600E-driven human cancers.

Yongxing Wu1,2, Liang Shi1, Yuelei Zhao1, Pu Chen1, Rongrong Cui1, Meiju Ji3, Nongyue He4, Maode Wang5, Gang Li6, Peng Hou7.   

Abstract

The activating TERT promoter mutations and BRAFV600E mutation are well-established oncogenic alterations in human cancers. Coexistence of BRAFV600E and TERT promoter mutations is frequently found in multiple cancer types, and is strongly associated with poor patient prognosis. Although the BRAFV600E-elicited activation of ERK has been demonstrated to contribute to TERT reactivation by maintaining an active chromatin state, it still remains to be addressed how activated ERK is selectively recruited to mutant TERT promoter. Here, we report that transcription factor GABPA mediates the regulation of BRAFV600E/MAPK signaling on TERT reactivation by selectively recruiting activated ERK to mutant TERT promoter, where activated ERK can phosphorylate Sp1, thereby resulting in HDAC1 dissociation and an active chromatin state. Meanwhile, phosphorylated Sp1 further enhances the binding of GABPA to mutant TERT promoter. Taken together, our data indicate that GABPA and Sp1 synergistically activate mutant TERT promoter, contributing to tumorigenesis and cancer progression, particularly in the BRAFV600E-driven human cancers. Thus, our findings identify a direct mechanism that bridges two frequent oncogenic alterations together in TERT reactivation.

Entities:  

Year:  2021        PMID: 33483600      PMCID: PMC7822828          DOI: 10.1038/s41698-020-00140-5

Source DB:  PubMed          Journal:  NPJ Precis Oncol        ISSN: 2397-768X


  50 in total

1.  The alpha and beta subunits of the GA-binding protein form a stable heterodimer in solution. Revised model of heterotetrameric complex assembly.

Authors:  Y Chinenov; M Henzl; M E Martin
Journal:  J Biol Chem       Date:  2000-03-17       Impact factor: 5.157

2.  The structure of GABPalpha/beta: an ETS domain- ankyrin repeat heterodimer bound to DNA.

Authors:  A H Batchelor; D E Piper; F C de la Brousse; S L McKnight; C Wolberger
Journal:  Science       Date:  1998-02-13       Impact factor: 47.728

3.  Interaction of Sp1 with the growth- and cell cycle-regulated transcription factor E2F.

Authors:  J Karlseder; H Rotheneder; E Wintersberger
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

4.  Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression.

Authors:  Ekta Khattar; Pavanish Kumar; Chia Yi Liu; Semih Can Akıncılar; Anandhkumar Raju; Manikandan Lakshmanan; Julien Jean Pierre Maury; Yu Qiang; Shang Li; Ern Yu Tan; Kam M Hui; Ming Shi; Yuin Han Loh; Vinay Tergaonkar
Journal:  J Clin Invest       Date:  2016-09-19       Impact factor: 14.808

Review 5.  Genomic and biochemical insights into the specificity of ETS transcription factors.

Authors:  Peter C Hollenhorst; Lawrence P McIntosh; Barbara J Graves
Journal:  Annu Rev Biochem       Date:  2011       Impact factor: 23.643

Review 6.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Authors:  Mingzhao Xing
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

7.  Sp1 and Sp3 physically interact and co-operate with GABP for the activation of the utrophin promoter.

Authors:  F Galvagni; S Capo; S Oliviero
Journal:  J Mol Biol       Date:  2001-03-09       Impact factor: 5.469

8.  The role of BRAF V600 mutation in melanoma.

Authors:  Paolo A Ascierto; John M Kirkwood; Jean-Jacques Grob; Ester Simeone; Antonio M Grimaldi; Michele Maio; Giuseppe Palmieri; Alessandro Testori; Francesco M Marincola; Nicola Mozzillo
Journal:  J Transl Med       Date:  2012-07-09       Impact factor: 5.531

9.  Increased expression of EHF via gene amplification contributes to the activation of HER family signaling and associates with poor survival in gastric cancer.

Authors:  Jing Shi; Yiping Qu; Xinru Li; Fang Sui; Demao Yao; Qi Yang; Bingyin Shi; Meiju Ji; Peng Hou
Journal:  Cell Death Dis       Date:  2016-10-27       Impact factor: 8.469

10.  Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.

Authors:  Rengyun Liu; Tao Zhang; Guangwu Zhu; Mingzhao Xing
Journal:  Nat Commun       Date:  2018-02-08       Impact factor: 14.919

View more
  2 in total

1.  Sorafenib decreases glycemia by impairing hepatic glucose metabolism.

Authors:  Jingjing Ma; Fang Sui; Yan Liu; Mengmeng Yuan; Hui Dang; Rui Liu; Bingyin Shi; Peng Hou
Journal:  Endocrine       Date:  2022-10-07       Impact factor: 3.925

2.  Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAFV600E-driven human cancers.

Authors:  Yongxing Wu; Liang Shi; Yuelei Zhao; Pu Chen; Rongrong Cui; Meiju Ji; Nongyue He; Maode Wang; Gang Li; Peng Hou
Journal:  NPJ Precis Oncol       Date:  2021-01-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.